p53 alteration in regional lymph node metastases from prostate carcinoma: A marker for progression?

Liang Cheng, Bradley C. Leibovich, Erik J. Bergstralh, Beth G. Scherer, Anna Pacelli, Dharamdas M. Ramnani, Horst Zincke, David G. Bostwick

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

BACKGROUND. Alterations of the p53 tumor suppressor gene are associated with advanced stage prostate carcinoma. The biologic significance of p53 nuclear accumulation in prostate cancer patients with regional lymph node metastases is uncertain. METHODS. The authors investigated p53 alterations by immunohistochemistry in 220 lymph node positive patients who were treated with radical prostatectomy, bilateral pelvic lymphadenectomy, and androgen deprivation therapy between 1987-1992 at the Mayo Clinic. The mean follow-up was 6.3 years. Tumor volume of lymph node metastases was measured using the grid method. RESULTS. p53 immunoreactivity was detected in 109 of 211 primary tumors (52%) and 83 of 144 matched regional lymph node metastases (58%); this expression was strongly concordant (correlation coefficient = 0.53; P = 0.0001). Overexpression of p53 protein in lymph node metastases was associated with distant metastasis free survival by univariate analysis (P = 0.03), but did not reach statistical significance by multivariate analysis (P = 0.07). Regional lymph node cancer volume was the single most important predictor of distant metastases after adjusting for Gleason score, DNA ploidy, and p53 expression. CONCLUSIONS. The findings of the current study suggest that assessment of biologic changes (including p53 alterations in regional lymph node metastases) could be of value in the assessment of the biologic aggressiveness of prostate carcinoma, whereas p53 expression in the primary tumor does not appear to influence patient outcome.

Original languageEnglish
Pages (from-to)2455-2459
Number of pages5
JournalCancer
Volume85
Issue number11
DOIs
StatePublished - Jun 1 1999

Fingerprint

Prostate
Lymph Nodes
Neoplasm Metastasis
Carcinoma
Neoplasms
Neoplasm Grading
Ploidies
Survival Analysis
Prostatectomy
Tumor Burden
Lymph Node Excision
Tumor Suppressor Genes
Androgens
Prostatic Neoplasms
Multivariate Analysis
Immunohistochemistry
DNA
Proteins

Keywords

  • Metastases
  • Progression
  • Prostate
  • Protein p53
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cheng, L., Leibovich, B. C., Bergstralh, E. J., Scherer, B. G., Pacelli, A., Ramnani, D. M., ... Bostwick, D. G. (1999). p53 alteration in regional lymph node metastases from prostate carcinoma: A marker for progression? Cancer, 85(11), 2455-2459. https://doi.org/10.1002/(SICI)1097-0142(19990601)85:11<2455::AID-CNCR22>3.0.CO;2-C

p53 alteration in regional lymph node metastases from prostate carcinoma : A marker for progression? / Cheng, Liang; Leibovich, Bradley C.; Bergstralh, Erik J.; Scherer, Beth G.; Pacelli, Anna; Ramnani, Dharamdas M.; Zincke, Horst; Bostwick, David G.

In: Cancer, Vol. 85, No. 11, 01.06.1999, p. 2455-2459.

Research output: Contribution to journalArticle

Cheng, L, Leibovich, BC, Bergstralh, EJ, Scherer, BG, Pacelli, A, Ramnani, DM, Zincke, H & Bostwick, DG 1999, 'p53 alteration in regional lymph node metastases from prostate carcinoma: A marker for progression?', Cancer, vol. 85, no. 11, pp. 2455-2459. https://doi.org/10.1002/(SICI)1097-0142(19990601)85:11<2455::AID-CNCR22>3.0.CO;2-C
Cheng, Liang ; Leibovich, Bradley C. ; Bergstralh, Erik J. ; Scherer, Beth G. ; Pacelli, Anna ; Ramnani, Dharamdas M. ; Zincke, Horst ; Bostwick, David G. / p53 alteration in regional lymph node metastases from prostate carcinoma : A marker for progression?. In: Cancer. 1999 ; Vol. 85, No. 11. pp. 2455-2459.
@article{52134d42cf56403cb5566a4a9181c933,
title = "p53 alteration in regional lymph node metastases from prostate carcinoma: A marker for progression?",
abstract = "BACKGROUND. Alterations of the p53 tumor suppressor gene are associated with advanced stage prostate carcinoma. The biologic significance of p53 nuclear accumulation in prostate cancer patients with regional lymph node metastases is uncertain. METHODS. The authors investigated p53 alterations by immunohistochemistry in 220 lymph node positive patients who were treated with radical prostatectomy, bilateral pelvic lymphadenectomy, and androgen deprivation therapy between 1987-1992 at the Mayo Clinic. The mean follow-up was 6.3 years. Tumor volume of lymph node metastases was measured using the grid method. RESULTS. p53 immunoreactivity was detected in 109 of 211 primary tumors (52{\%}) and 83 of 144 matched regional lymph node metastases (58{\%}); this expression was strongly concordant (correlation coefficient = 0.53; P = 0.0001). Overexpression of p53 protein in lymph node metastases was associated with distant metastasis free survival by univariate analysis (P = 0.03), but did not reach statistical significance by multivariate analysis (P = 0.07). Regional lymph node cancer volume was the single most important predictor of distant metastases after adjusting for Gleason score, DNA ploidy, and p53 expression. CONCLUSIONS. The findings of the current study suggest that assessment of biologic changes (including p53 alterations in regional lymph node metastases) could be of value in the assessment of the biologic aggressiveness of prostate carcinoma, whereas p53 expression in the primary tumor does not appear to influence patient outcome.",
keywords = "Metastases, Progression, Prostate, Protein p53, Survival",
author = "Liang Cheng and Leibovich, {Bradley C.} and Bergstralh, {Erik J.} and Scherer, {Beth G.} and Anna Pacelli and Ramnani, {Dharamdas M.} and Horst Zincke and Bostwick, {David G.}",
year = "1999",
month = "6",
day = "1",
doi = "10.1002/(SICI)1097-0142(19990601)85:11<2455::AID-CNCR22>3.0.CO;2-C",
language = "English",
volume = "85",
pages = "2455--2459",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - p53 alteration in regional lymph node metastases from prostate carcinoma

T2 - A marker for progression?

AU - Cheng, Liang

AU - Leibovich, Bradley C.

AU - Bergstralh, Erik J.

AU - Scherer, Beth G.

AU - Pacelli, Anna

AU - Ramnani, Dharamdas M.

AU - Zincke, Horst

AU - Bostwick, David G.

PY - 1999/6/1

Y1 - 1999/6/1

N2 - BACKGROUND. Alterations of the p53 tumor suppressor gene are associated with advanced stage prostate carcinoma. The biologic significance of p53 nuclear accumulation in prostate cancer patients with regional lymph node metastases is uncertain. METHODS. The authors investigated p53 alterations by immunohistochemistry in 220 lymph node positive patients who were treated with radical prostatectomy, bilateral pelvic lymphadenectomy, and androgen deprivation therapy between 1987-1992 at the Mayo Clinic. The mean follow-up was 6.3 years. Tumor volume of lymph node metastases was measured using the grid method. RESULTS. p53 immunoreactivity was detected in 109 of 211 primary tumors (52%) and 83 of 144 matched regional lymph node metastases (58%); this expression was strongly concordant (correlation coefficient = 0.53; P = 0.0001). Overexpression of p53 protein in lymph node metastases was associated with distant metastasis free survival by univariate analysis (P = 0.03), but did not reach statistical significance by multivariate analysis (P = 0.07). Regional lymph node cancer volume was the single most important predictor of distant metastases after adjusting for Gleason score, DNA ploidy, and p53 expression. CONCLUSIONS. The findings of the current study suggest that assessment of biologic changes (including p53 alterations in regional lymph node metastases) could be of value in the assessment of the biologic aggressiveness of prostate carcinoma, whereas p53 expression in the primary tumor does not appear to influence patient outcome.

AB - BACKGROUND. Alterations of the p53 tumor suppressor gene are associated with advanced stage prostate carcinoma. The biologic significance of p53 nuclear accumulation in prostate cancer patients with regional lymph node metastases is uncertain. METHODS. The authors investigated p53 alterations by immunohistochemistry in 220 lymph node positive patients who were treated with radical prostatectomy, bilateral pelvic lymphadenectomy, and androgen deprivation therapy between 1987-1992 at the Mayo Clinic. The mean follow-up was 6.3 years. Tumor volume of lymph node metastases was measured using the grid method. RESULTS. p53 immunoreactivity was detected in 109 of 211 primary tumors (52%) and 83 of 144 matched regional lymph node metastases (58%); this expression was strongly concordant (correlation coefficient = 0.53; P = 0.0001). Overexpression of p53 protein in lymph node metastases was associated with distant metastasis free survival by univariate analysis (P = 0.03), but did not reach statistical significance by multivariate analysis (P = 0.07). Regional lymph node cancer volume was the single most important predictor of distant metastases after adjusting for Gleason score, DNA ploidy, and p53 expression. CONCLUSIONS. The findings of the current study suggest that assessment of biologic changes (including p53 alterations in regional lymph node metastases) could be of value in the assessment of the biologic aggressiveness of prostate carcinoma, whereas p53 expression in the primary tumor does not appear to influence patient outcome.

KW - Metastases

KW - Progression

KW - Prostate

KW - Protein p53

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0033151791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033151791&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19990601)85:11<2455::AID-CNCR22>3.0.CO;2-C

DO - 10.1002/(SICI)1097-0142(19990601)85:11<2455::AID-CNCR22>3.0.CO;2-C

M3 - Article

C2 - 10357418

AN - SCOPUS:0033151791

VL - 85

SP - 2455

EP - 2459

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -